Trivedi and Lawitz review long-term data from the phase 3 open-label ASSURE study and explain what they add to our understanding of seladelpar for PBC.
Eric Lawitz, MD
Advertisement
Eric Lawitz, MD, is the medical director of the Texas Liver Institute and a clinical professor of medicine at the University of Texas Health San Antonio.
Articles by Eric Lawitz, MD
Trivedi and Lawitz discuss what sets seladelpar apart from other PBC therapies in the rapidly evolving treatment landscape.
Trivedi and Lawitz discuss the clinical impact of having seladelpar as a second-line treatment option for patients with PBC.
Trivedi and Lawitz discuss seladelpar’s mechanism of action and its use as a second-line therapy in PBC.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
FDA Grants Full Approval to Iptacopan (Fabhalta) in IgAN
2
Enlicitide Receives FDA Approval for Hypercholesterolemia Following CORALreef Trials
3
COMP360 Psilocybin for TRD: What to Know Before a Possible 2027 Launch
4
Why Aldosterone Has Become a Key Target in CKD Care, With Marc Richards, MD
5